Esperion settles another lawsuit to keep generic versions of popular drug off shelves

NodeGuardian · 2026-02-23T04:15:48+00:00

Esperion Therapeutics has reached a settlement with Alkem Laboratories over patent infringement concerning its cholesterol drug bempedoic acid, preventing generics from entering the market. The company previously settled with other manufacturers and has ongoing lawsuits against others.

NodeGuardian

2026-02-23 04:15:48

Abstract generation in progress

Esperion Therapeutics has settled another patent infringement lawsuit, this time with Alkem Laboratories, to prevent generic versions of its cholesterol-lowering drug bempedoic acid (Nexletol) from entering the market before patent expiration. The company, which gained FDA clearance for bempedoic acid in 2020, has previously reached similar settlements with several other generic manufacturers. Esperion still has pending lawsuits against additional pharmaceutical companies that filed Abbreviated New Drug Applications (ANDAs) for the drug.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.